Receipt date: 04/01/2011

Page 1 of 1

							Page 1 of 1	
Form PTO-144		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. DFM0004/US		l l	Serial No. 10/566,145	
INFORMATION DISCLOSURE					Applicant Peter Prehm			
STATEMENT BY APPLICANT				Filing Date		Grou	Group	
				Dogomi	ber 20, 20	07 1614		
		FOREIGN PATE	NT DOC			07 1014		
Examiner	Document	Date	Country		Class	Subclass	oclass Translatio	
Initial	Number						Yes/No	
	1 136 552	09/2001	E	P				
	92/16226	10/1992	W	0				
	95/20385	08/1995	W	O				
	96/03497	02/1996	W	O			English	
							Abstract	
	98/08538	03/1998	W					
	98/48784	11/1998	W	O				
	232-234. (with Benedetti, A., e. Reduces Hepati Fibrosis, Hepate	English translation tal. (1997) Treatm c Stellate Cells Actiology 26: 334A.	of first a ent with i ivation ar	nd last p Amiloria nd Colla	aragraph o le, A Na+/ gen Depos	of page 233) H+ Exchang ition in Expe	er Inhibitor, rimental Liver	
	Med Chir. 27: 8							
 Woo, T., et al. (1984) Nifedipine in Scelroderma Ulcerations, International Dermatology 23: 678-680. App, E., et al. (1990) Acute and Long-term Amiloride Inhalation in Cystic 								
	American Revie	w of Respiratory D	Disease 14	41: 605-6	612.	•		
	Dong, R., et al. (1992) Verapamil Ameliorates the Clinical and Pathological Course of Murine Myocarditis, Journal of Clinical Investigation 90: 2022-2030. Lake-Bakaar, G., et al. (1995) Dose-Dependent Effect of Continuous Subcutaneous							
	Verapamil Infus Sciences 40: 23	sion on Experimente 49-2355.	al Acute I	Pancrea	titis in Mic	e, Digestive	Diseases and	
	Rejections in Hy Transplantation		Transplan	ıt Recipi	ents, Nepl	rology Dialy	sis/	
through citation	nitial if citation considing if not in conformance							
applicant. #60818						Page 1 of 2		

Page 1 of 2

Form PTO-1449	•	Atty. Docket No.	Serial No.					
	Patent and Trademark Office	DFM0004/US	10/566,145					
		Applicant						
\mathbf{n}	NFORMATION DISCLOSURE	- FF						
	TATEMENT BY APPLICANT	Peter Prehm						
		Filing Date	Group					
-		December 20, 2007 1614						
0	THER DOCUMENTS (Including Author, T	itle, Date, Pertinent Pages	, Etc.)					
Yang, JL., et al. (2001) Effect of nifedipine in metastatic colon cancer with DNA								
	mismatch repair gene defect, Lancet (North American Edition) 357: 1767-1768.							
	Andersson, R., et al. (2003) Effects of Interferon-a, verapamil and dacarbazine in the							
	treatment of advanced malignant melanoma, Melanoma Research 13: 87-91.							
	Robert, J. (1999) Multidrug resistance in oncology: diagnostic and therapeutic approaches, European Journal of Clinical Investigation 29: 536-545.							
	Laliberte, R., et al. (1994) Tenidap Modulates Cytoplasmic pH and Inhibits Anion							
	Transport In Vitro, Journal of Immunology 153: 2168-2179.							
	Harris, R., et al. (1995) Clinical Activity of Leukotriene Inhibitors, International Journal of							
	Immunopharmacology 17: 147-156.							
	Harris, M., et al. (2000) Effect of Low Dose Daily Aspirin on Serum Urate Levels and							
	Urinary Excretion in Patients Receiving Probenecid for Gouty Arthritis, Journal of							
	Rheumatology 27: 2873-2876.							
	Bröll, H., et al. (1975) Long time therapy with Benzbromaron in patients with arthritis							
	urica, Wiener Medizinische Wochenschrift 128: 546-548. (with English translation of Discussion section)							
	Kagan, G., et al. (1981) Flufenamic Acid and Placebo Compared in Rheumatoid Arthritis							
	and Osteoarthritis, Journal of International Medical Research 9: 253-256.							
	Appelboom, T. et al. (1994) Proglumetacin Versus Indometacin in Rheumatoid Arthritis:							
	A Double-Blind Multicenter Study, Advances in Therapy 11: 228-234.							
!	Jorgensen, C., et al. (2000) Multidrug resistances genes in rheumatology, Joint Bone							
	Spine 67: 8-10.	ut Ditt						
	Salmon, S., et al. (1996) Relevance of Multidrug Resistance to Rheumatoid Arthritis:							
Development of a New Therapeutic Hypothesis, Journal of Rheumatology 23: 97-101. EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line								
through citation if not in conformance and not considered. Include copy of this form with next communication to								
applicant.								
#60818		Page 2	of 2					

/Gregg Polansky/